FUNCTIONAL CONSTRAINTS AGAINST VARIATIONS ON MOLECULES FROM THE TISSUE-LEVEL - SLOWLY EVOLVING BRAIN-SPECIFIC GENES DEMONSTRATED BY PROTEIN-KINASE AND IMMUNOGLOBULIN SUPERGENE FAMILIES
FUNCTIONAL CONSTRAINTS AGAINST VARIATIONS ON MOLECULES FROM THE TISSUE-LEVEL - SLOWLY EVOLVING BRAIN-SPECIFIC GENES DEMONSTRATED BY PROTEIN-KINASE AND IMMUNOGLOBULIN SUPERGENE FAMILIES
复制标题
DOI：
10.1093/oxfordjournals.molbev.a040181
复制
发表时间：
1995-01-01
影响因子：
10.7
通讯作者：
MIYATA, T
中科院分区：
文献类型：
--
作者：
KUMA, K;IWABE, N;MIYATA, T
在蛋白激酶家族中，激酶结构域的基本功能在成员之间是相似的。根据功能约束的标准观点，分子进化速率取决于单个分子的功能和结构特征（局部约束）。因此，激酶结构域的进化速率预期对于不同成员是相似的。与这一预期相反，进化速率的比较显示了成员之间的巨大差异;最大和最小速率之间的差异约为100倍。在免疫球蛋白（IG）家族成员中也发现了类似的结果。此外，显着的相关性，在进化速率之间的激酶结构域和Ig样结构域的受体蛋白酪氨酸激酶和激酶结构域和SH结构域之间的非受体型激酶。此外，在组织中表达的家族成员的进化速率差异很大，这取决于它们的组织分布：在大脑中表达的成员的进化速率明显低于在免疫系统中表达的成员。这些结果有力地表明存在另一种约束（全局约束），以防止来自更高水平（如组织或器官）的分子发生变化。
In the protein kinase family, the basic function of kinase domain is similar among members. According to the standard view of functional constraint, the molecular evolutionary rate depends on functional and structural features characteristic of individual molecules (local constraint). Thus the evolutionary rate of the kinase domain is expected to be similar for different members. Contrary to this expectation, a comparison of the evolutionary rates revealed a wide difference among members; it amounts to about 100 times difference between the maximum and minimum rates. A similar result was also found in members of the immunoglobulin (Ig) family. In addition, significant correlations in evolutionary rate were observed between the kinase domain and the Ig-like domain in the receptor protein tyrosine kinases and between the kinase domain and the SH domain in the nonreceptor-type kinases. Furthermore, the evolutionary rates of family members that are expressed tissue specifically differ widely, depending on their tissue distribution: members expressed in the brain evolve with significantly slower rates than those expressed in the immune system. These results strongly suggest the presence of an alternative constraint (global constraint) against changes on molecules derived from higher levels like tissues or organs.